NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$93.35 +1.52 (+1.66 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$93.35
Today's Range$88.27 - $95.11
52-Week Range$58.03 - $133.74
Volume2.98 million shs
Average Volume1.36 million shs
Market Capitalization$2.77 billion
P/E Ratio-6.49
Dividend YieldN/A
Beta1.88
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.96 million
Book Value$0.65 per share

Profitability

Net Income$-360,360,000.00
Net Margins-202.93%

Miscellaneous

Employees507
Market Cap$2.77 billion
Next Earnings Date2/28/2019 (Confirmed)
OptionableOptionable

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, topping the consensus estimate of ($2.65) by $0.47. The biopharmaceutical company earned $47 million during the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. Intercept Pharmaceuticals's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the company earned ($2.89) EPS. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

21 equities research analysts have issued 1 year price targets for Intercept Pharmaceuticals' stock. Their predictions range from $68.00 to $248.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $149.3684 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)
  • 2. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC. Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. While we are pleased with the approval of Ocaliva, the company’s dependence on a single product for growth has its risks. Any negative news related to Ocaliva would adversely impact Intercept and its growth prospects. The lack of other candidates in the pipeline is concerning. Nevertheless, the company is looking to expand the drug’s label in the promising NASH and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Shares have outperformed the industry in the last six months." (2/15/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Press coverage about ICPT stock has trended neutral recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), Celgene (CELG), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Biogen (BIIB), Allergan (AGN) and Regeneron Pharmaceuticals (REGN).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Mark E. Pruzanski, President, Chief Executive Officer & Director
  • Jerome B. Durso, Chief Operating Officer
  • Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer
  • David A. Shapiro, Chief Medical Officer
  • Christian Weyer, Executive Vice President-Research & Development

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (3.31%), BB Biotech AG (1.94%), Two Sigma Investments LP (1.05%), Eagle Asset Management Inc. (0.96%), Northern Trust Corp (0.90%) and Geode Capital Management LLC (0.88%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Elk Creek Partners LLC, Biondo Investment Advisors LLC, South Dakota Investment Council, Pinnacle Associates Ltd., Millennium Management LLC, MetLife Investment Advisors LLC and Virtus ETF Advisers LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski, SPA Genextra and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Two Sigma Investments LP, Sofinnova Investments Inc., Two Sigma Advisers LP, BB Biotech AG, Canada Pension Plan Investment Board, Assenagon Asset Management S.A. and Geode Capital Management LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $93.35.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.77 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  888 (Vote Outperform)
Underperform Votes:  501 (Vote Underperform)
Total Votes:  1,389
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel